Bioventus Inc.

Annual Trend FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Net income (loss) $6.3m $14.7m $9.6m ($213.4m) ($195.6m) ($43.8m) $27.3m
Less: Loss from discontinued operations, net of tax $1.8m $0 $0 ($68.7m) ($74.4m) $0 $0
Income (loss) from continuing operations $8.1m $14.7m $9.6m ($144.7m) ($121.2m) ($43.8m) $27.3m
Depreciation and amortization $30.3m $28.6m $34.9m $66.8m $57.4m $49.6m $47.0m
Deferred income taxes ($348k) ($511k) ($9.8m) ($52.8m) ($2.4m) ($5.4m) ($909k)
Impairments of assets $0 $0 $199.5m $78.6m $36.4m $0
Loss on extinguishment $3.4m $0 $2.2m $0 $0 $0 $326k
Provision (benefit) for expected credit losses $2.2m $1.2m $485k $5.2m ($1.1m) ($434k) $1.3m
Equity-based compensation $0 $0 $19.8m $17.6m $2.7m $10.1m $12.7m
Change in fair value of contingent consideration $0 $0 $829k $6.5m $719k $1.4m $0
Loss on disposals $0 $0 $3.6m $292k $81k
Unrealized (gain) loss on foreign currency fluctuations ($490k) $472k $1.4m $665k ($259k) ($360k)
Other, net ($448k) $317k ($37k) ($15k) ($506k) ($758k) ($827k)
Accounts receivable ($14.9m) ($3.9m) ($20.1m) ($18.0m) $10.1m ($10.7m) ($916k)
Inventory ($1.4m) ($528k) $3.2m ($18.6m) ($6.0m) ($16.4m) $8.6m
Accounts payable and accrued expenses $6.6m $20.5m $18.2m $10.9m ($5.3m) $17.8m ($19.8m)
Other current and noncurrent assets and liabilities ($3.9m) ($733k) ($14.6m) $11.2m ($2.0m) ($2.5m) ($1.7m)
(Settlement) proceeds from the sale of a business $34.7m $24.7m ($686k)
Purchase of property and equipment ($2.3m) ($4.1m) ($7.4m) ($10.0m) ($7.4m) ($1.0m) ($2.6m)
Investments and acquisition of distribution rights ($6.0m) ($16.6m) ($13.5m) ($1.5m) $0 ($709k) $0
Tax withholdings on equity-based compensation $0 $0 ($3.4m) $0 $0 ($9k)
Receipt of deferred consideration $0 $0 $4.5m $0
Payment of contingent consideration $0 $0 ($19.8m)
Borrowing on revolver $0 $49.0m $20.0m $25.0m $64.0m $0 $45.0m
Payment on revolver $0 ($49.0m) ($20.0m) ($25.0m) ($49.0m) ($15.0m) ($45.0m)
Debt financing costs $0 $0 ($3.7m) ($1.2m) ($697k)
Accrued liabilities for distribution rights and member distributions $3.2m $0 $709k $0 $0
Accounts payable for purchase of property, plant and equipment $34k $336k $695k $419k $1.3m $42k $240k
Net cash from operating activities - continuing operations $42.5m $72.2m $23.0m ($13.5m) $17.5m $38.8m $74.7m
Net cash from operating activities - discontinued operations ($1.8m) ($400k) $0 $0 ($2.2m) $0 $0
Net cash from operating activities $40.7m $71.8m $23.0m ($13.5m) $15.3m $38.8m $74.7m
Net cash from investing activities - continuing operations ($7.9m) ($20.7m) ($283.8m) ($116.4m) $27.3m $23.0m ($3.2m)
Net cash from investing activities - discontinued operations $0 $172k $0 $0 ($11.5m) $0 $0
Net cash from investing activities ($7.9m) ($20.5m) ($283.8m) ($116.4m) $15.8m $23.0m ($3.2m)
Proceeds from the issuance of long-term debt, net of discount $198.1m $0 $257.5m $79.7m $0 $0 $31.9m
Payments on the extinguishment of long-term debt $0 $0 ($65.8m)
Payments on long-term debt ($199.5m) ($10.0m) ($91.2m) ($20.0m) ($38.3m) ($44.6m) ($9.1m)
Proceeds from issuance of Class A and B common stock $0 $0 $1.6m $5.8m $778k $2.4m $2.1m
Net cash from financing activities ($11.0m) ($29.6m) $273.4m $62.1m ($26.7m) ($54.6m) ($62.1m)
Effect of exchange rate changes on cash ($104k) $589k ($228k) $521k $629k ($2.6m) $371k
Net change in cash and cash equivalents $21.7m $22.3m $12.4m ($67.4m) $5.1m $4.6m $9.7m
Cash and cash equivalents at the beginning of the period $64.5m $86.8m $99.2m $31.8m $37.0m $41.6m $51.2m